Best iPhone Notes App for Genetic Counselors

Genetic counselors operate at the intersection of complex science and deeply personal patient conversations. You're interpreting variant classifications, explaining inheritance patterns, supporting families through devastating diagnoses, and coordinating with oncologists, cardiologists, and obstetricians. Your professional effectiveness depends on staying current with a rapidly evolving field and being exceptionally prepared for each consultation.

HIPAA critical note: Never store patient-identifying information (name, DOB, MRN, insurance, specific test results, diagnosis details, family information that could identify individuals) in personal apps including Nemos. All patient PHI belongs in your EHR. Personal notes should be generic clinical observations, educational content, and professional reference material — never patient-specific.

What Genetic Counselors Use Nemos For (PHI-free)

Clinical education notes. The field of genetic counseling changes constantly — new variant classifications, updated guidelines, new testing modalities, emerging therapies. Nemos captures your continuing education in a searchable format.

Consultation preparation reminders. General preparation notes for consultation types — not patient-specific. "Checklist: BRCA counseling" or "Lynch syndrome risk explanation framework" that you've developed and refine over time.

Professional reference notes. Risk assessment frameworks, recurrence risk numbers, genetic penetrance data, standard test sensitivity/specificity ranges. Your personal clinical reference that supplements your training.

Protocol and guideline notes. Updated NSGC, ACMG, or specialty society guidelines that affect your practice. When guidelines change, you need to know.

Supervision and professional development notes. Learning observations from complex cases (de-identified), questions to bring to supervision, reflections on communication approaches.

How Nemos Works for Genetic Counselors

Clinical Quick Reference Notes

"BRCA1/2 — Clinical Reference (updated 2025-03): Lifetime risk with BRCA1: breast ~72%, ovarian ~44%. Lifetime risk with BRCA2: breast ~69%, ovarian ~17%. Updated per NSGC 2025 guideline revision. Cascade testing: first-degree relatives recommended once proband variant confirmed. Insurance: GINA protects employment/health insurance; does not cover life/disability."

Consultation Framework Notes

"Lynch syndrome counseling checklist (personal workflow): 1. Confirm universal tumor screening done (IHC/MSI) if applicable. 2. Review family history pedigree before consultation. 3. Explain MMR gene function and how variants cause cancer risk. 4. Risk numbers: colon ~40–80% lifetime (variant-specific), endometrial ~25–60%. 5. Surveillance: colonoscopy every 1–2 years starting age 20–25. 6. Cascade testing plan: discuss which relatives benefit from testing. 7. Psychosocial support resources: provide before and after result disclosure."

Variant Interpretation Reference Notes

"Variant classification reminder (ACMG 2015 + updates): VUS to pathogenic: requires additional evidence accumulation. Explain to patient: result may be reclassified; re-contact policy varies by lab. Current reclassification rate: ~5–7% of VUS reclassified per year. Labs to check for reclassification: ClinVar, lab-specific variant databases."

Supervision Preparation Notes

Notes to bring to clinical supervision (fully de-identified):

"Supervision topic 2025-03-15: challenging communication scenario — pediatric case where parents interpreted VUS as 'negative.' Discuss approach to correcting that interpretation without undermining trust. Also: patient who declined cascade testing despite being an obligate carrier — ethical framework for when to re-contact?"

Professional Development Notes

From conferences or webinars:

"NSGC 2025 Annual Conference notes: - New ACMG classification criteria for splicing variants — significant reclassification expected in cardiovascular genes - Polygenic risk scores (PRS): clinical implementation accelerating — check current institutional policy - Telegenetics expansion: several presentations on population health models — read JGCPD summary article"

FAQ

Q: What if I take a quick note about a complex case during a consultation? A: Use only generic clinical identifiers — no names, dates of birth, or other PHI. "Young patient with strong family history of ovarian cancer, BRCA VUS" is not PHI; "Jane Smith, DOB 1985, MRN 44712" is PHI and must not go in personal apps.

Q: Can I use Nemos for variant classification notes? A: For general variant classification education and reference notes, yes. For patient-specific variant interpretation tied to an identifiable patient, no — that belongs in the EHR.

Q: What about notes from multidisciplinary team meetings? A: Notes from MDT discussions that don't reference specific patients (case patterns, management frameworks, protocol discussions) are appropriate. Patient-specific MDT notes belong in the EHR.

Q: How do I keep my clinical reference notes current? A: Add "updated" dates to key reference notes and review when relevant guidelines change. Outdated genetic risk estimates can be actively harmful if used in patient counseling.

Q: Is Nemos appropriate for storing pedigree sketches? A: Not for identifiable patient pedigrees. For generic educational pedigrees illustrating inheritance patterns, yes.

Related Reading

• /blog/clinical-researcher-notes-iphone
• /blog/research-coordinator-notes-iphone
• /blog/nurse-practitioner-notes-iphone
• /blog/physician-notes-iphone

Sources

• National Society of Genetic Counselors (NSGC) practice guidelines and professional standards
• American College of Medical Genetics and Genomics (ACMG) variant classification criteria
• ClinGen evidence-based variant curation frameworks